Home/ Stocks/ RFL

Rafael Holdings, Inc. Class B Common Stock

RFL XNYS

$2.24 +0.12 (+5.66%) ▲ 15-min delayed

Open

$2.16

High

$2.50

Low

$2.16

Volume

899.6K

Market Cap

$116.48M

About Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 23 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2026	$179.0K	$-2,898,000	$-0.08
Q2 2026	$211.0K	$-6,327,000	$-0.13
Q1 2026	$240.0K	$-9,797,000	$-0.19
FY 2025	$917.0K	$-30,643,000	$-1.04

Related Market News

No specific coverage for RFL yet. Check out our latest market news or earnings calendar.

Get RFL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Rafael Holdings, Inc. Class B Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.